vialroom

#retatrutide 2026-02-15

Sunday33 messages9 participantstimes are UTC
Highlights from this day
  • split_shipment — triple agonist meaning GLP-1, GIP and glucagon, have i got that right 20:03
  • VialBot — On this day 3 years ago this channel logged 23 messages. 20:28
  • split_shipment — anyone gone above 7.5 and what changed 20:31
  • lisbon_lot — the purity spread across lots worries me more than the molecule does 21:08
ZZ

i log resting heart rate every morning because of this and its the one number i actually watch, for what its worth

the heart rate thing is real enough that i mention it whenever someone asks about starting

low and slow

phase 2 doses are published and theyre not far off what people here run, coincidence rather than plan

IT

energy expenditure isnt something i could feel, though my sleep tracker disagreed with me

ZZ

the honest position is this has less human evidence behind it than anything else discussed here

[edited]
IT

TRIUMPH is the phase 3 programme, thats the name to search rather than the molecule

RS

there is no long term safety data, phase 2 and an ongoing phase 3 programme is what exists

🔥1
SS

triple agonist meaning GLP-1, GIP and glucagon, have i got that right

🧊6
RS

low and slow here means smaller steps than i ever used on tirzepatide, thats the received wisdom

VB

On this day 3 years ago this channel logged 23 messages.

SS

anyone gone above 7.5 and what changed

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.

did anyone come off because of the heart rate

is the glucagon arm what people mean by the energy expenditure thing

does the energy expenditure claim show up as anything you can feel
phase 2 was still trending at the end which is why the phase 3 readout matters more than usual

SS

research use only is on every vial and i treat it as exactly that, nobody here is prescribing

LL

the glucagon arm is the mechanistic story for extra energy expenditure and its still a story to me, take that with a pinch of salt

LL

the purity spread across lots worries me more than the molecule does

Cited study
Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
New England Journal of Medicine · 2023
48 weeks, dose-ranging. A Phase 2 result is not a safety record.